Endoscopic Tri-Modal Imaging versus standard video endoscopy for the detection of early neoplasia in patients with low-grade dysplasia in a Barrett's oesophagus: a multicentre randomised cross-over controlled study
ISRCTN | ISRCTN91816824 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN91816824 |
Secondary identifying numbers | N/A |
- Submission date
- 01/02/2007
- Registration date
- 01/02/2007
- Last edited
- 04/07/2011
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Jacques Bergman
Scientific
Scientific
Academic Medical Center (AMC)
Department of Gastroenterology
P.O. Box 22660
Amsterdam
1100 DD
Netherlands
Phone | +31 (0)20 566 3556 |
---|---|
j.j.bergman@amc.uva.nl |
Study information
Study design | Randomised, crossover multicentre trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Not specified |
Study type | Treatment |
Scientific title | |
Study acronym | GETMI |
Study objectives | Endoscopic Tri-Modal Imaging (ETMI) increases the detection rate of early neoplasia in Barrett's oEsophagus (BE) patients with 40% or more compared to Standard Video Endoscopy (SVE). |
Ethics approval(s) | Approval received from the local medical ethics committee on the 10th August 2006 (ref: MEC 05/068). |
Health condition(s) or problem(s) studied | Barrett's oesophagus |
Intervention | ETMI-gastroscopy and standard video gastroscopy |
Intervention type | Other |
Primary outcome measure | 1. Number of patients with early neoplasia detected with ETMI or SVE 2. Number of lesions with early neoplasia detected with ETMI and SVE |
Secondary outcome measures | 1. Number of early neoplastic lesions detected with AutoFluorescence Imaging (AFI) only 2. Reduction of false positives findings after detailed Narrow Band Imaging (NBI) evaluation |
Overall study start date | 01/01/2007 |
Completion date | 31/12/2008 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Not Specified |
Target number of participants | 96 |
Key inclusion criteria | 1. Barrett's oesophagus patients with low-grade dyplasia comfirmed by two expert GastroIntestinal (GI) pathologists 2. Written informed consent |
Key exclusion criteria | 1. Presence of active erosive oesophagitis grade A according to the Los Angeles classification of erosive oesophagitis 2. Presence of conditions precluding histological sampling of the oesophagus (e.g. oesophageal varices, coagulation disorders, anticoagulant therapy) 3. Less than 18 years |
Date of first enrolment | 01/01/2007 |
Date of final enrolment | 31/12/2008 |
Locations
Countries of recruitment
- Netherlands
Study participating centre
Academic Medical Center (AMC)
Amsterdam
1100 DD
Netherlands
1100 DD
Netherlands
Sponsor information
Academic Medical Centre (AMC) (The Netherlands)
Hospital/treatment centre
Hospital/treatment centre
Department of Gastroenterology
P.O. Box 22660
Amsterdam
1100 DD
Netherlands
Website | http://www.amc.uva.nl |
---|---|
https://ror.org/03t4gr691 |
Funders
Funder type
Research organisation
The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 01/02/2011 | Yes | No |